BPIQ Pro/Elite/Apex Investor Posts

Updated targets for the Top 10 , Top 15 , and Top 20  BPIQ Elite model portfolios are now available. 👇

Summary

FYI - We updated our targets for our Run-Up fund and started making trades towards the new targets today.

As we have discussed in prior posts , we transitioned our BPIQ model portfolios to strategies that utilized top holdings of bio/pharma-focused funds. This post updates the performance of those model portfolios in their first full year. Furthermore, this post presents results of more back-testing we performed as we tested similar and further refined sub-strategies based on hedge-fund favorite holdings. Four conclusions can be drawn from this work:

Summary

We updated our Top 10, Top 15, and Top 20 biopharma-focused Hedge fund favorite portfolios targets earlier this week. The updates are based on Q4 holdings of top biopharma hedge funds. The Top 20 hedge fund portfolio strategy uses a different methodology for identifying top holdings than the Top 10 portfolio and Top 15 portfolio. We plan to make trades in the coming week to align the holdings of these portfolios with the updated targets.

2024 was a remarkable year for cell and gene therapies (CGT) with the FDA approving nine innovative products. Read more below about these approved CGT therapies and new indications.

The following table provides info on the companies discussed in this article, including EV, short interest, current top biopharma-hedge fund holdings, and BPIQ portfolio holding percentages.

The 43rd Annual J.P. Morgan Health Care Conference  is taking place in San Francisco, CA from January 13-16, 2025 .

We’re always excited to find bio/pharma companies nearing their therapeutic product launch!

This post provides some ideas on how to Use BPIQ's Hedge Fund Data And Model Portfolios to Beat the Major Biotech ETFs.

TAKE HOME MESSAGE:

You can find updated Q3 bioHF holdings data at app.bpiq.com/hedgefunds

This weekend COGT reports some Big-Mover data on  Bezuclastinib (CGT9486) at ASH.

SUMMARY

BACKGROUND

SUMMARY

At BPIQ, our goal is to help you make money investing in smid-cap biopharma stocks

See our post " Two Strategies to Make Money in a Biopharma Down Market " for key strategies to make money regardless of whether XBI is in an upward or downward trend

See our post " Two Strategies to Make Money in a Biopharma Down Market " for key strategies to make money regardless of whether XBI is in an upward or downward trend